Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Fitusiran (ALN-AT3SC) in Healthy Volunteers and Hemophilia A or B
NCT02035605Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2014
- Primary completion
- Jul 2017
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
Phase 1, randomised, single-blind trial in hemophilia A and hemophilia B (HB) comparing Fitusiran with Placebo (2 arms). Primary endpoint: Safety of ALN-AT3SC at Day 112. Started Jan 2014; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02035605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035605.